Population-based assessment of disease-free survival (DFS) as a surrogate endpoint (SE) of 5-year overall survival (5Y OS) in stage I-III rectal (RC) and colon cancer (CC).

被引：0
|
作者：
Lee-Ying, Richard M.
Yin, Yaling
Lim, Howard John
Cheung, Winson Y.
Kennecke, Hagen F.
机构：
[1] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[2] British Columbia Canc Agcy, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.3602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3602
引用
收藏
页数：2
相关论文
共 29 条
  • [21] Durable improvement in disease-free survival (DFS) and overall survival (OS) for stage II or III colon cancer treated with leucovorin-modulated fluorouracil (FL): 10-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol C-03.
    O'Connell, MJ
    Wolmark, N
    Yothers, G
    Haile, S
    Colangelo, L
    Petrelli, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 248S - 248S
  • [22] Improved three-year disease-free survival for patients with FIGO stage I ovarian cancer without capsule rupture during surgery: A population-based study
    Paulsen, T.
    Kaern, J.
    Trope, C.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S112 - S113
  • [23] EFFICACY FINDINGS FROM THE X-ACT TRIAL OF CAPECITABINE VS. 5-FU/LV AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER: NO IMPACT OF AGE ON DISEASE-FREE SURVIVAL OR OVERALL SURVIVAL
    Twelves, C.
    Scheithauer, W.
    McKendrick, J.
    Nowacki, M.
    Seitz, J.
    Van Hazel, G.
    Wong, A.
    Diaz-Rubio, E.
    Gilberg, F.
    Cassidy, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
  • [24] EFFICACY FINDINGS FROM THE X-ACT TRIAL OF CAPECITABINE VS. 5-FU/LV AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER: NO IMPACT OF AGE ON DISEASE-FREE SURVIVAL OR OVERALL SURVIVAL
    Twelves, C.
    Scheithauer, W.
    McKendrick, J.
    Nowacki, M.
    Seitz, J.
    van Hazel, G.
    Wong, A.
    Diaz-Rubio, E.
    Gilberg, F.
    Cassidy, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 207 - 207
  • [25] IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
    Wakelee, Heather A.
    Altorki, Nasser K.
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor O.
    Goloborodko, Oleksandr
    Rittmeyer, Achim
    Reck, Martin
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Fu, Chenqi
    Ballinger, Marcus
    Deng, Yu
    Srivastava, Minu K.
    Bennett, Elizabeth
    Gitlitz, Barbara Jenifer
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8035 - LBA8035
  • [26] Is 3-yrs disease-free-survival (DFS) a reliable surrogate end-point for predicting 5-yrs overall-survival (OS) benefit in adjuvant taxane-based chemotherapy for breast cancer (BC)? Analysis of randomized clinical trials (RCTS)
    Ciccarese, Mariangela
    Bria, Emilio
    Cuppone, Federica
    Carlini, Paolo
    Milella, Michele
    Sperduti, Isabella
    Lo Russo, Vito
    Nistico, Cecilia
    Terzoli, Edmondo
    Cognetti, Francesco
    Giannarelli, Diana
    ANNALS OF ONCOLOGY, 2007, 18 : 51 - 51
  • [27] Comparing 5-Year Survival Rates Before and After Re-stratification of Stage I-III Right-Sided Colon Cancer Patients by Establishing the Presence/Absence of Occult Tumor Cells and Lymph Node Metastases in the Different Levels of Surgical Dissection
    Banipal, G. S.
    Stimec, B., V
    Andersen, S. N.
    Faerden, A. E.
    Edwin, B.
    Baral, J.
    Nesgaard, J. M.
    Benth, J. Saltyte
    Ignjatovic, D.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2022, 26 (10) : 2201 - 2211
  • [28] POSTOPERATIVE RADIOTHERAPY IN RESECTED STAGE III-N2 NON-SMALL CELL LUNG CANCER (NSCLC): CAN 3D-CONFORMAL RADIOTHERAPY IMPROVE THE 5-YEAR OVERALL SURVIVAL (OS) IN PATIENTS WITH PERSISTENT N2 DISEASE AFTER INDUCTION CHEMOTHERAPY?
    Billiet, C.
    Gouw, Z.
    Decaluwe, H.
    Peeters, S.
    Vansteenkiste, J.
    Dooms, C.
    De Leyn, P.
    De Ruysscher, D.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S34 - S34
  • [29] Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803
    Sargent, D. J.
    Yothers, G.
    Van Cutsem, E.
    Cassidy, J.
    Saltz, L.
    Wolmark, N.
    Shi, Q.
    Buyse, M.
    de Gramont, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
123